首页> 外文期刊>Current therapeutic research, clinical and experimental. >Estimation of minimum whole-blood tacrolimus concentration for therapeutic drug monitoring with plasma prednisolone concentration: A retrospective cohort study in Japanese kidney transplant recipients
【24h】

Estimation of minimum whole-blood tacrolimus concentration for therapeutic drug monitoring with plasma prednisolone concentration: A retrospective cohort study in Japanese kidney transplant recipients

机译:用血浆泼尼松龙浓度估算用于治疗药物的最低全血他克莫司浓度:日本肾脏移植受者的一项回顾性队列研究

获取原文
获取原文并翻译 | 示例
           

摘要

Background: In immunosuppressive therapy administered after organ transplantation, therapeutic drug monitoring (TDM) of tacrolimus must be performed frequently because of the large variation in its pharmacokinetic properties and a progressive decrease in dose requirements. An indicator for estimating the target minimum whole-blood tacrolimus concentration (Cmin TAC) would be useful to minimize the number of blood samplings required for tacrolimus TDM.Objectives: The primary objective of this study was to investigate whether plasma prednisolone concentration, postoperative days (POD) and AUC 0 to 9 hours before transplantation (AUC0–9int) are useful indicators of tacrolimus TDM. The secondary objective was to determine the usefulness of blood tacrolimus concentration as an indicator of the development of nontraumatic, glucocorticoid-induced necrosis of the femoral head, an adverse event that has been associated with the use of prednisolone in vivo.Methods: This open-label, nonrandomized, retrospective study was conducted at the Department of Transplantation and Regenerative Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan. Data from 43 male and 22 female patients (mean age, 38 years [range, 9–64 years]) who received a living-related kidney transplant from 2001 to 2004 were included. Multiple blood samplings were performed to determine AUC0–9int, AUC 0 to 9 hours after drug administration and after transplantation (AUC0–9), Cmin TAC, Cmax, and Tmax after transplantation. The correlations between each parameter were determined. The correlation between POD and the changes in tacrolimus bioavailability was investigated using the indicator, defined as the tacrolimus dose required to maintain the target (10–15 ng/mL) Cmin TAC (dose/C10–15). Correlations between dose/C10–15 and AUC0–9int (3 AUC0–9int groups, defined as follows: low, medium, and high [<93, 93?≤152, and 152 ng·h/mL, respectively]) were determined. Correlations between mean Cmin values of prednisolone at a dose of 40 mg on PODs 4 to 11 (Cmin PSL40) and Cmin TAC, or AUC0–9int were determined. A subanalysis was used to determine the relationship between dose/C10–15 and the prevalence of nontraumatic, glucocorticoid-induced necrosis of the femoral head.Results:Cmin TAC was found to be significantly correlated with AUC0–9int (r=0.554; P<0.001) and Cmin PSL40 (r=0.336; P<0.001). In the low-AUC0–9int group, dose/C10–15 was higher than that of the other groups (P<0.001). AUC0–9int was significantly correlated with Cmin PSL40 (r=0.445; P<0.001)). Dose/C10–15 in the patient group that had necrosis of the femoral head was lower than that of the group without necrosis (n=6; P<0.01).Conclusions:The results of this small, retrospective study suggest that Cmin PSL40, AUC0–9int, and POD were significant predictors of Cmin TAC. These parameters were found to be a useful indicator of tacrolimus TDM in these Japanese transplant recipients. Our results also suggest that dose/C10–15 and AUC0–9int might be useful indicators for estimating the risk for nontraumatic, steroid-induced necrosis of the femoral head.
机译:背景:在器官移植后进行的免疫抑制治疗中,他克莫司的治疗药物监测(TDM)必须频繁进行,因为他克莫司的药代动力学特性存在较大差异,并且剂量要求逐渐降低。估计目标最低全血他克莫司浓度(Cmin TAC)的指标将有助于减少他克莫司TDM所需的血液采样数量。 POD)和移植前0至9小时的AUC(AUC0-9int)是他克莫司TDM的有用指标。次要目的是确定他克莫司血药浓度作为非创伤性,糖皮质激素诱发的股骨头坏死发展的指标的有用性,这是与泼尼松龙在体内使用相关的不良事件。标签,非随机回顾性研究是在日本京都府立医科大学的移植与再生外科系进行的。纳入了2001年至2004年接受生活性肾脏移植的43例男性和22例女性患者(平均年龄38岁[范围9-64岁])的数据。进行多次采血以确定AUC0–9int,给药后和移植后0至9小时的AUC(AUC0–9),移植后的Cmin TAC,Cmax和Tmax。确定每个参数之间的相关性。使用指示剂研究了POD与他克莫司生物利用度变化之间的相关性,该指标定义为维持目标(10-15 ng / mL)Cmin TAC(剂量/ C10-15)所需的他克莫司剂量。确定了剂量/ C10-15与AUC0-9int之间的相关性(3个AUC0-9int组,定义如下:低,中和高[分别为<93、93?≤152和152 ng·h / mL]) 。确定了在剂量为40 mg的POD 4-11上泼尼松龙的平均Cmin值(Cmin PSL40)与Cmin TAC或AUC0-9int之间的相关性。亚分​​析用于确定剂量/ C10-15与非创伤性糖皮质激素引起的股骨头坏死发生率之间的关系。结果:发现Cmin TAC与AUC0-9int显着相关(r = 0.554; P < 0.001)和Cmin PSL40(r = 0.336; P <0.001)。在低AUC0–9int组中,剂量/ C10–15高于其他组(P <0.001)。 AUC0-9int与Cmin PSL40显着相关(r = 0.445; P <0.001)。股骨头坏死患者组的剂量/ C10-15低于无坏死组(n = 6; P <0.01)。结论:这项小型回顾性研究的结果表明,Cmin PSL40, AUC0-9int和POD是Cmin TAC的重要预测因子。发现这些参数是这些日本移植受者中他克莫司TDM的有用指标。我们的结果还表明,剂量/ C10-15和AUC0-9int可能是评估非创伤性,类固醇诱发的股骨头坏死风险的有用指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号